GlassScriptPhysician profile
Antonio J Ramos
NPI 1063424992
$3,366.89
in general payments reported to CMS, 2019-2025
32 companies · $706 in 2025
The $706 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $619 · 2020: $387 · 2021: $278 · 2022: $356 · 2023: $655 · 2024: $365 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,726.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $539.10 | 2021-2025 | |
| Lilly USA, LLC | $427.69 | 2019-2025 | Mounjaro, Jardiance |
| Pfizer INC. | $281.61 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $281.37 | 2019-2025 | Airsupra, Farxiga |
| Amarin Pharma, INC. | $245.14 | 2019-2022 | |
| Glaxosmithkline, LLC. | $236.38 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $180.54 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Janssen Pharmaceuticals, INC | $124.60 | 2022-2023 | Xarelto |
| Amgen INC. | $98.28 | 2019-2023 | Prolia, Evenity |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $94.42 | 2023 | Lifevest |
| Exact Sciences Corporation | $88.01 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $85.43 | 2019-2020 | |
| Biogen, INC. | $83.94 | 2025 | Spinraza |
| Astellas Pharma US INC | $76.57 | 2019-2023 | Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $64.55 | 2023-2024 | Rexulti |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $59.40 | 2022 | |
| Sanofi-Aventis U.S. LLC | $41.46 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $40.19 | 2020-2022 | |
| Scilex Pharmaceuticals INC. | $33.07 | 2024 | |
| Sumitomo Pharma America, INC. | $30.57 | 2024-2025 | Myfembree, Gemtesa |
| Avanir Pharmaceuticals, INC. | $29.85 | 2019 | |
| Merck Sharp & Dohme LLC | $29.44 | 2020 | |
| Abbott Laboratories | $26.91 | 2022-2025 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $25.67 | 2019-2020 | |
| Edwards Lifesciences Corporation | $25.62 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.11 | 2020 | |
| Gilead Sciences, INC. | $19.35 | 2024 | |
| Mirum Pharmaceuticals, INC. | $17.28 | 2024 | Livmarli |
| Phadia US INC. | $16.03 | 2023 | Immunocap |
| Arbor Pharmaceuticals, INC. | $15.46 | 2019 | |
| Sunovion Pharmaceuticals INC. | $15.19 | 2021 | |
| Shield Therapeutics INC | $12.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.